GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track

GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track

Source: 
Xconomy
snippet: 

GlaxoSmithKline’s years-long oncology resurgence is on track to have two new drugs approved in the US in mid-2020, after the company won a key first-line ovarian cancer indication for Zejula (niraparib) in April. The belantamab mafodotin and dostarlimab approvals also anticipated this year will give GSK its first commercial footholds in the immuno-oncology market – one of four cancer drug categories where the company is developing new therapies.